Find Research outputs

Search results

• 2022

  All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors

  Bree, K. K., Hensley, P. J., Lobo, N., Brooks, N. A., Nogueras-Gonzalez, G. M., Guo, C. C., Navai, N., Grossman, H. B., Dinney, C. P. & Kamat, A. M., Aug 1 2022, In: Journal of Urology. 208, 2, p. 284-291 8 p.

  Research output: Contribution to journal › Article › peer-review
  2 Scopus citations

• Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

  Schild, S. E., Wang, X., Bestvina, C. M., Williams, T., Masters, G., Singh, A. K., Stinchcombe, T. E., Salama, J. K., Wolf, S., Zemla, T., Duma, N., Chun, S. G., Amini, A., Kozono, D. & Watt, C., Jul 2022, In: Clinical Lung Cancer. 23, 5, p. e317-e320

  Research output: Contribution to journal › Article › peer-review

• Allium vegetables: Traditional uses, phytoconstituents, and beneficial effects in inflammation and cancer

  Alam, A., Al Arif Jahan, A., Bari, M. S., Khandokar, L., Mahmud, M. H., Junaid, M., Chowdhury, M. S., Khan, M. F., Seidel, V. & Haque, M. A., 2022, (Accepted/In press) In: Critical Reviews in Food Science and Nutrition.

  Research output: Contribution to journal › Review article › peer-review
  1 Scopus citations

• Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  Bashir, Q., Milton, D. R., Popat, U. R., Kebriaei, P., Hosing, C., Khouri, I. F., Rezvani, K., Nieto, Y., Oran, B., Srour, S. A., Saini, N. Y., Olson, A. L., Ahmed, S., Al-Atrash, G., Rondon, G., Konopleva, M. Y., Champlin, R. E., Shpall, E. J., Qazilbash, M. H. & Pemmaraju, N., Jan 2022, In: Bone marrow transplantation. 57, 1, p. 51-56 6 p.

  Research output: Contribution to journal › Article › peer-review
  10 Scopus citations

• Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis

  Hamadani, M., Gopal, A. K., Pasquini, M., Kim, S., Qiu, X., Ahmed, S., Lazaryan, A., Raj Bhatt, V., Daly, A., Lulla, P., Ciurea, S., Gauthier, J., Agrawal, V., Grover, N. S., Lekakis, L., Modi, D., Dahi, P. B., Herr, M. M., Connor Johnson, P., Hashmi, H., & 2 othersHematti, P. & Locke, F. L., Jan 25 2022, In: Blood Advances. 6, 2, p. 486-494 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  6 Scopus citations

• Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease

  Docampo, M. D., da Silva, M. B., Lazrak, A., Nichols, K. B., Lieberman, S. R., Slingerland, A. E., Armijo, G. K., Shono, Y., Nguyen, C., Monette, S., Dwomoh, E., Lee, N., Geary, C. D., Perobelli, S. M., Smith, M., Markey, K. A., Vardhana, S. A., Kousa, A. I., Zamir, E., Greenfield, I., & 6 othersSun, J. C., Cross, J. R., Peled, J. U., Jenq, R. R., Stein-Thoeringer, C. K. & van den Brink, M. R. M., Apr 14 2022, In: Blood. 139, 15, p. 2392-2405 14 p.

  Research output: Contribution to journal › Article › peer-review
  5 Scopus citations

• A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

  TRACERx Consortium, Jun 2022, In: Nature Cancer. 3, 6, p. 696-709 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  3 Scopus citations

• Alterations of theMdm2C-Terminus Differentially Impact Its Function In Vivo

  Pant, V., Aryal, N. K., Xiong, S., Chau, G. P., Fowlkes, N. W. & Lozano, G., Apr 1 2022, In: Cancer Research. 82, 7, p. 1313-1320 8 p.

  Research output: Contribution to journal › Article › peer-review

• Alternative adenosine Receptor activation: The netrin-Adora2b link

  Yuan, X., Mills, T., Doursout, M. F., Evans, S. E., Vidal Melo, M. F. & Eltzschig, H. K., Jul 15 2022, In: Frontiers in Pharmacology. 13, 944994.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

• Always be prepared for success

  Westin, J., Mar 31 2022, In: Blood. 139, 13, p. 1928-1930 3 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

• ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform

  Klec, C., Knutsen, E., Schwarzenbacher, D., Jonas, K., Pasculli, B., Heitzer, E., Rinner, B., Krajina, K., Prinz, F., Gottschalk, B., Ulz, P., Deutsch, A., Prokesch, A., Jahn, S. W., Lellahi, S. M., Perander, M., Barbano, R., Graier, W. F., Parrella, P., Calin, G. A., & 1 othersPichler, M., Jul 2022, In: Cellular and Molecular Life Sciences. 79, 7, 391.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  1 Scopus citations

• A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer

  Franco, P., Segelov, E., Johnsson, A., Riechelmann, R., Guren, M. G., Das, P., Rao, S., Arnold, D., Spindler, K. L. G., Deutsch, E., Krengli, M., Tombolini, V., Sebag-Montefiore, D. & De Felice, F., Apr 1 2022, In: Cancers. 14, 7, 1697.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  1 Scopus citations

• AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma

  AIDS Malignancy Consortium (AMC), Jun 15 2022, In: Clinical Cancer Research. 28, 12, p. 2646-2656 11 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• A mechanistic modeling framework reveals the key principles underlying tumor metabolism

  Tripathi, S., Park, J. H., Pudakalakatti, S., Bhattacharya, P. K., Kaipparettu, B. A. & Levine, H., Feb 2022, In: PLoS computational biology. 18, 2, e1009841.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary

  Yip, L., Duh, Q. Y., Wachtel, H., Jimenez, C., Sturgeon, C., Lee, C., Velázquez-Fernández, D., Berber, E., Hammer, G. D., Bancos, I., Lee, J. A., Marko, J., Morris-Wiseman, L. F., Hughes, M. S., Livhits, M. J., Han, M. A., Smith, P. W., Wilhelm, S., Asa, S. L., Fahey, T. J., & 3 othersMcKenzie, T. J., Strong, V. E. & Perrier, N. D., Oct 2022, In: JAMA Surgery. 157, 10, p. 870-877 8 p.

  Research output: Contribution to journal › Article › peer-review
  3 Scopus citations

• American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy

  Shah, C., Vicini, F., Beriwal, S., Thaker, N., Frank, S. J., Rossi, P., Orio, P., Chang, A. J., Joshi, N., Campbell, S. R., Naghavi, A., Chao, S., Kamrava, M., Deufel, C. L., Mourtada, F. & Suh, J. H., Jan 1 2022, In: Brachytherapy. 21, 1, p. 63-74 12 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• American Cancer Society nutrition and physical activity guideline for cancer survivors

  Rock, C. L., Thomson, C. A., Sullivan, K. R., Howe, C. L., Kushi, L. H., Caan, B. J., Neuhouser, M. L., Bandera, E. V., Wang, Y., Robien, K., Basen-Engquist, K. M., Brown, J. C., Courneya, K. S., Crane, T. E., Garcia, D. O., Grant, B. L., Hamilton, K. K., Hartman, S. J., Kenfield, S. A., Martinez, M. E., & 10 othersMeyerhardt, J. A., Nekhlyudov, L., Overholser, L., Patel, A. V., Pinto, B. M., Platek, M. E., Rees-Punia, E., Spees, C. K., Gapstur, S. M. & McCullough, M. L., May 1 2022, In: CA Cancer Journal for Clinicians. 72, 3, p. 230-262 33 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access
  32 Scopus citations

• American College of Surgeons Commission on Cancer Standard 5.7 for Total Mesorectal Excision for Mid-to-Low Rectal Cancer

  Adams, A. M., Vreeland, T. J., Teshome, M., Francescatti, A. B., Zheng, L., Hunt, K. K., Katz, M. H. & Messick, C. A., Jun 1 2022, In: Journal of the American College of Surgeons. 234, 6, p. 1249-1253 5 p.

  Research output: Contribution to journal › Article › peer-review

• American College of Surgeons Commission on Cancer Standard for Curative-intent Pulmonary Resection

  Nissen, A. P., Vreeland, T. J., Teshome, M., Archer, M. A., Francescatti, A. B., Katz, M. H. G., Hunt, K. K., Zheng, L. & Mullett, T. W., Jan 2022, In: Annals of Thoracic Surgery. 113, 1, p. 5-8 4 p.

  Research output: Contribution to journal › Editorial › peer-review
  2 Scopus citations

• American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

  Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., Cabanillas, M. E., Dabekaussen, K., Davies, L., Dias-Santagata, D., Fagin, J. A., Faquin, W. C., Ghossein, R. A., Gopal, R. K., Miyauchi, A., Nikiforov, Y. E., & 11 othersRingel, M. D., Robinson, B., Ryder, M. M., Sherman, E. J., Sadow, P. M., Shin, J. J., Stack, B. C., Tuttle, R. M., Wirth, L. J., Zafereo, M. E. & Randolph, G. W., Jun 2022, In: Head and Neck. 44, 6, p. 1277-1300 24 p.

  Research output: Contribution to journal › Article › peer-review
  2 Scopus citations

• American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

  Amini, A., Verma, V., Simone, C. B., Chetty, I. J., Chun, S. G., Donington, J., Edelman, M. J., Higgins, K. A., Kestin, L. L., Movsas, B., Rodrigues, G. B., Rosenzweig, K. E., Rybkin, I. I., Slotman, B. J., Wolf, A. & Chang, J. Y., Feb 1 2022, In: International Journal of Radiation Oncology Biology Physics. 112, 2, p. 361-375 15 p.

  Research output: Contribution to journal › Article › peer-review
  10 Scopus citations

• A Method for Orthotopic Transplantation of Lung Cancer in Mice

  Wilson, A. N., Chen, B., Liu, X., Kurie, J. M. & Kim, J., 2022, Methods in Molecular Biology. Humana Press Inc., p. 231-242 12 p. (Methods in Molecular Biology; vol. 2374).

  Research output: Chapter in Book/Report/Conference proceeding › Chapter
  1 Scopus citations

• Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

  Krueger, C. K., Bruno, J. J., Tverdek, F. P., Hernandez, M. & Abudayyeh, A., 2022, (Accepted/In press) In: Annals of Pharmacotherapy.

  Research output: Contribution to journal › Article › peer-review

• AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy

  Kambhampati, S., Eghtedar, A., McMahon, C., de Botton, S., Pigneux, A., Ball, B., Borthakur, G., Volkert, A., Gausman, J. A., Baker, K., Hodgson, G., Warlick, E., Roth, D., Kelly, M., Pollyea, D. & Stein, E., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S213

  Research output: Contribution to journal › Article › peer-review

• AML-109 Preliminary Results of MT-401 in Post-Transplant Measurable Residual Disease Positive (MRD+) Acute Myeloid Leukemia (AML) Patients

  Arslan, S., Hsu, J., Oran, B., Sica, A., Liu, H., Silverman, M., Bejanyan, N., DiStasi, A., McCallum, R., Quintero, S., Garrett, G., Wang, K., Smith, E., Hoang, T., Shahim, T., Crisostomo, J., Wilga-Savitski, A., Pickering, J., Angelo, L., Smith, A., & 2 othersVera, J. & Koneru, M., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S213-S214

  Research output: Contribution to journal › Article › peer-review

• AML-119 The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)

  DiNardo, C., Pratz, K., Panayiotidis, P., Wei, X., Vorobyev, V., Illés, À., Kim, I., Ivanov, V., Ku, G., Miller, C., Zhang, M., Tatsch, F., Potluri, J., Schmidt, X. & Recher, C., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S214

  Research output: Contribution to journal › Article › peer-review

• AML-142 Patients at High Risk of Relapse Post-Transplant: A Phase 1 Study Design With a Novel Treatment Strategy Using the Estimand Framework

  Al-Atrash, G., Craddock, C., Schmid, C., Xu, Y., Weber, H. J., Eldjerou, L., Weber, S., Widmer, L. & Zeiser, R., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S216-S217

  Research output: Contribution to journal › Article › peer-review

• AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC)

  Daver, N. G., Wei, A. H., Stein, E. M., DeAngelo, D. J., Pathak, D., Xu, Y., Grzesiak, S. & Venditti, A., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S217

  Research output: Contribution to journal › Article › peer-review

• AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas

  Nishida, Y., Scruggs, D. A., Ayoub, E., Patsilevas, T., Ruvolo, V. R., Mak, P. Y., Carter, B. Z., Boettcher, S., Maiti, A., Zhou, Q., Yang, Z., Yan, H., Ma, L. & Andreeff, M., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S218

  Research output: Contribution to journal › Article › peer-review

• AML-250 Mitochondrial Respiration Regulates GPX4 Inhibition-Induced Ferroptosis in Acute Myeloid Leukemia

  Akiyama, H., Zhao, R., Nishida, Y., Ostermann, L., Mak, P. Y., Ayoub, E., Piya, S., Carter, B. Z., Andreeff, M. & Ishizawa, J., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S229

  Research output: Contribution to journal › Article › peer-review

• AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

  Erba, H. P., Pollyea, D. A., Sekeres, M. A., Garcia-Manero, G., Seiter, K., DeGutis, I. S., Kiselev, P., McBride, A., Yu, E. & Roboz, G. J., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S229-S230

  Research output: Contribution to journal › Article › peer-review

• AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration

  Bidikian, A., Kantarjian, H. M., Dabaja, B., Ravandi, F., Jabbour, E., DiNardo, C., Borthakur, G., Daver, N., Garcia-Manero, G., Kadia, T., Sasaki, K. & Issa, G., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S233-S234

  Research output: Contribution to journal › Article › peer-review

• AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)– Based Regimen

  Abuasab, T., Senapati, J., Kadia, T., Ravandi, F., DiNardo, C., Pemmaraju, N., Ohanion, M., Alvarado, Y., Kantarjian, H. M. & Borthakur, G., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S235-S236

  Research output: Contribution to journal › Article › peer-review

• AML-326 Novel FLT3-ALK2 Dual Inhibitor TP-0184 Inhibits Leukemia Growth by Targeting Serine Biosynthesis in FLT3-ITD-Positive AML Cells

  Tyagi, A., Ly, S., Yuan, B., El-Dana, F., Jaggupilli, A., Foulks, J., Warner, S. & Battula, V. L., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S236

  Research output: Contribution to journal › Article › peer-review

• AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice

  Tyagi, A., Ly, S., El-Dana, F., Yuan, B., Jaggupilli, A., Grimm, S., Bover, L., Buhring, H. J. & Battula, V. L., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S236

  Research output: Contribution to journal › Article › peer-review

• AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy

  Abuasab, T., Alvarado, Y., Issa, G., Islam, R., James, N., Yilmaz, M., Jain, N., Masarova, L., Kornblau, S., Jabbour, E., Pemmaraju, N., Bravo, G. M., Pierce, S., DiNardo, C., Kadia, T., Daver, N., Konopleva, M., Garcia-Manero, G. & Ravandi, F., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S237

  Research output: Contribution to journal › Article › peer-review

• AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia

  Bazinet, A., Kantarjian, H., Borthakur, G., Yilmaz, M., Bose, P., Jabbour, E., Alvarado, Y., Chien, K., Pemmaraju, N., Takahashi, K., Short, N., Daver, N., Issa, G., Jain, N., Bull-Linderman, D., DiNardo, C., Montalban-Bravo, G., Garcia-Manero, G., Sasaki, K., Ravandi, F., & 1 othersKadia, T., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S239-S240

  Research output: Contribution to journal › Article › peer-review

• AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies

  Lachowiez, C., Borthakur, G., Loghavi, S., Zeng, Z., Kadia, T., Masarova, L., Takahashi, K., Tippett, G., Garcia, J., Bose, P., Jabbour, E., Ravandi, F., Daver, N., Manero, G. G., Vyas, P., Kantarjian, H., Konopleva, M. & DiNardo, C., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S240-S241

  Research output: Contribution to journal › Article › peer-review

• AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD)

  Abuasab, T., Mohamed, S. F., Biostatistics, H. H., Biostatistics, X. W., Sasaki, K., Yilmaz, M., Kadia, T., DiNardo, C., Daver, N., Pemmaraju, N., Ravandi, F., Kantarjian, H. M., Garcia-Manero, G. & Takahashi, K., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S243

  Research output: Contribution to journal › Article › peer-review

• AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

  Martinelli, G., Santoro, A., Gambacorti-Passerini, C., Polo, S. V., Solomon, S. R., Mukherjee, S., Lech-Maranda, E., Levy, M. Y., Wierzbowska, A., Calbacho-Robles, M., Marconi, G., Giannini, M. B., Cano, I., Miñana, L. T., Acuña-Cruz, E., Angelosanto, N., Mughal, T. I., Galleu, A., Blotta, S., Ravandi, F., & 1 othersMontesinos, P., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S243-S244

  Research output: Contribution to journal › Article › peer-review

• AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation

  Daver, N., Affinito, J., Cai, H., Dobrowolska, H., Eguchi, K., Stoudemire, J., Watanabe, A. & Hitron, M., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S244

  Research output: Contribution to journal › Article › peer-review

• AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy

  Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C., Angelucci, E., Vinti, L., Mughal, T. I. & Pawlowska, A., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S244-S245

  Research output: Contribution to journal › Article › peer-review

• AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

  Pammaraju, N., Kantarjian, H. M., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., Patnaik, M. M., & 2 othersMughal, T. I. & Konopleva, M., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S246-S247

  Research output: Contribution to journal › Article › peer-review

• AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)

  Vyas, P., Daver, N., Chao, M., Xing, G., Renard, C., Ramsingh, G. & Sallman, D., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S247

  Research output: Contribution to journal › Article › peer-review

• AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

  DiNardo, C. D., de Botton, S., Risueño, A., Schuh, A. C., Löwenberg, B., Kim, H. J., Vyas, P., Wei, A. H., Stein, E. M., Döhner, H., Fathi, A. T., Martin-Regueira, P., Taningco, L., Bluemmert, I., Yu, X., See, W. L. & Hasan, M., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S249-S250

  Research output: Contribution to journal › Article › peer-review

• AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

  Ravandi, F., Wei, A. H., Döhner, H., Sayar, H., Montesinos, P., Dombret, H., Selleslag, D., Porkka, K., Jang, J. H., Skikne, B., Beach, C. L., Tian, Y. & Roboz, G. J., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S252-S253

  Research output: Contribution to journal › Article › peer-review

• AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results

  Daver, N., Vyas, P., Kambhampati, S., Malki, M. A., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J. & Sallman, D., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S253-S254

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement

  Pemmaraju, N., Konopleva, M., Sweet, K., Stein, A., Vasu, S., Rizzieri, D., Wang, E. S., Kantarjian, H. M., Brooks, C., Mughal, T. & Lane, A., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S254

  Research output: Contribution to journal › Article › peer-review

• AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34)

  Ong, F., Kadia, T., Short, N. J., Yilmaz, M., Alvarado, Y., Sasaki, K., Pierce, S. A., Garcia-Manero, G., DiNardo, C., Borthakur, G., Konopleva, M., Daver, N., Kantarjian, H. M. & Ravandi, F., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S258

  Research output: Contribution to journal › Article › peer-review

• AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies

  Saengboon, S., Ramdial, J., Saini, N., Olson, A. L., Im, J., Hosing, C., Popat, U., Shpall, E., Champlin, R. E. & Srour, S., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S259-S260

  Research output: Contribution to journal › Article › peer-review